Evolocumab for preventing major cardiovascular events in adults with a high risk of cardiovascular events

Evolocumab is currently in clinical development for the prevention of major cardiovascular events in adults without prior heart attack or stroke who are at high risk of a cardiovascular event. Cardiovascular disease (CVD) is an umbrella term for all diseases of the heart and circulation. It includes everything from conditions that are inherited or that a person is born with, to those that are develop later, such as coronary heart disease (CHD), atrial fibrillation, heart failure, and stroke. Risk factors of CVD include high blood pressure, diabetes, high cholesterol, smoking, and air pollution. There is a need for safer and more effective treatment options as standard treatment options have limited efficacy.